Effects of stable transfection of human fetal osteoblast cells with estrogen receptor-alpha on regulation of gene expression by tibolone

Bone

Volumn 39, Issue 3, 2006, Pages 523-529

  Maran, A ^a   Shogren, K ^a   Zhang, M ^a   Yaszemski, M J ^a   Hefferan, T E ^a   Spelsberg, T C ^b   Kloosterboer, H J ^c   Turner, R T ^d  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c NV ORGANON   (Netherlands)

^d OREGON STATE UNIVERSITY   (United States)

Author keywords

Alkaline phosphatase; Anti estrogen; Bone formation; Osteoporosis; Type 1 collagen

Indexed keywords

3ALPHA HYDROXYTIBOLONE; 3BETA HYDROXYTIBOLONE; ALKALINE PHOSPHATASE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; TIBOLONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; ENZYME ACTIVITY; FETUS; FETUS CELL; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; NONHUMAN; OPTIMAL DRUG DOSE; OSTEOBLAST; RAT;

ALKALINE PHOSPHATASE; ANIMALS; BONE MARROW; BONE MATRIX; CELLS, CULTURED; ESTROGEN RECEPTOR ALPHA; FETUS; GENE EXPRESSION REGULATION; HUMANS; NORPREGNENES; OSTEOBLASTS; RATS; STROMAL CELLS; SULFATASES; SULFATES; TRANSFECTION;

EID: 33746750879     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.03.006     Document Type: Article

References (36)

1. Gallagher J.C., Baylink D.J., Freeman R., and McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J. Clin. Endocrinol. Metab. 86 (2001) 4717-4726
2. Reed M.J., Woo L.W., Robinson J.J., Leblond B., Leese M.P., Purohit A., et al. 2-difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor. Biochem. Biophys. Res. Commun. 317 (2004) 169-175
3. Kloosterboer H.J., and Ederveen A.G. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/-progestogen) treatments. J. Steroid. Biochem. Mol. Biol. 83 (2002) 157-165
4. de Gooyer M.E., Kleyn G.T., Smits K.C., Ederveen A.G., Verheul H.A., and Kloosterboer H.J. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol. Cell. Endocrinol. 183 (2001) 55-62
5. Timmer C.J., and Huisman J.A. Effect of a standardized meal on the bioavailability of a single oral dose of tibolone 2.5 mg in healthy postmenopausal women. Pharmacotherapy 22 (2002) 310-315
6. de Gooyer M.E., Deckers G.H., Schoonen W.G., Verheul H.A., and Kloosterboer H.J. Receptor profiling and endocrine interactions of tibolone. Steroids 68 (2003) 21-30
7. Landgren M.B., Bennink H.J., Helmond F.A., and Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. Br. J. Obstet. Gynaecol. 109 (2002) 1109-1114
8. Lindsay R., Hart D.M., and Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br. Med. J. 280 (1980) 1207-1209
9. Ederveen A.G., and Kloosterboer H.J. Tibolone, a steroid with a tissue-specific hormonal profile, completely prevents ovariectomy-induced bone loss in sexually mature rats. J. Bone Miner. Res. 14 (1999) 1963-1970
10. Yoshitake K., Yokota K., Kasugai Y., Kagawa M., Sukamoto T., and Nakamura T. Effects of 16 weeks of treatment with tibolone on bone mass and bone mechanical and histomorphometric indices in mature ovariectomized rats with established osteopenia on a low-calcium diet. Bone 25 (1999) 311-319
11. Evans G., Bryant H.U., Magee D., Sato M., and Turner R.T. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134 (1994) 2283-2288
12. Lonard D.M., and Smith C.L. Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids 67 (2002) 15-24
13. Gustafsson J.A. Therapeutic potential of selective estrogen receptor modulators. Curr. Opin. Chem. Biol. 2 (1998) 508-511
14. Smith C.L., Nawaz Z., and O'Malley B.W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11 (1997) 657-666
15. Harris S.A., Enger R.J., Riggs B.L., and Spelsberg T.C. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J. Bone Miner. Res. 10 (1995) 178-186
16. Robinson J.A., Harris S.A., Riggs B.L., and Spelsberg T.C. Estrogen regulation of human osteoblastic cell proliferation and differentiation. Endocrinology 138 (1997) 2919-2927
17. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162 (1987) 156-159
18. Maran A., Zhang M., Spelsberg T.C., and Turner R.T. The dose-response effects of ethanol on the human fetal osteoblastic cell line. J. Bone Miner. Res. 16 (2001) 270-276
19. Maran A., Zhang M., Kennedy A.M., Sibonga J.D., Rickard D.J., Spelsberg T.C., et al. 2-methoxyestradiol induces interferon gene expression and apoptosis in osteosarcoma cells. Bone 30 (2002) 393-398
20. Elger W., Schwarz S., Hedden A., Reddersen G., and Schneider B. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Mol. Biol. 55 (1995) 395-403
21. Purohit A., Vernon K.A., Hummelinck A.E., Woo L.W., Hejaz H.A., Potter B.V., et al. The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J. Steroid. Biochem. Mol. Biol. 64 (1998) 269-275
22. Kloosterboer H.J. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 48 Suppl. 1 (2004) S30-S40
23. Kloosterboer H.J. Tibolone: a steroid with a tissue-specific mode of action. J. Steroid. Biochem. Mol. Biol. 76 (2001) 231-238
24. Bjarnason N.H., Bjarnason K., Haarbo J., Rosenquist C., and Christiansen C. Tibolone: prevention of bone loss in late postmenopausal women.[see comment]. J. Clin. Endocrinol. Metab. 81 (1996) 2419-2422
25. Bjarnason N.H., Bjarnason K., Hassager C., and Christiansen C. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone 20 (1997) 151-155
26. Rymer J., Robinson J., and Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric 5 (2002) 390-398
27. Chetrite G.S., and Pasqualini J.R. The selective estrogen enzyme modulator (SEEM) in breast cancer. J. Steroid. Biochem. Mol. Biol. 76 (2001) 95-104
28. Tang B., Markiewicz L., Kloosterboer H.J., and Gurpide E. Human endometrial 3 beta-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14). J. Steroid. Biochem. Mol. Biol. 45 (1993) 345-351
29. Kloosterboer H.J. Tissue-selective effects of tibolone on the breast. Maturitas 49 (2004) S5-S15
30. Pasqualini J.R., Gelly C., and Lecerf F. Estrogen sulfates: biological and ultrastructural responses and metabolism in MCF-7 human breast cancer cells. Breast Cancer Res. Treat. 8 (1986) 233-240
31. Pasqualini J.R., and Lecerf F. Ultrastructural modifications provoked by tamoxifen either alone or combined with oestradiol in the uteri of fetal or newborn guinea-pigs. J. Endocrinol. 110 (1986) 197-202
32. Ederveen A.G., and Kloosterboer H.J. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J. Bone Miner. Res. 16 (2001) 1651-1657
33. Dubey R.K., Gillespie D.G., Grogli M., Kloosterboer H.J., and Imthurn B. Tibolone and its metabolites induce antimitogenesis in human coronary artery smooth muscle cells: role of estrogen, progesterone, and androgen receptors. J. Clin. Endocrinol. Metab. 89 (2004) 852-859
34. Simoncini T., Mannella P., Fornari L., Caruso A., Varone G., Garibaldi S., et al. Tibolone activates nitric oxide synthesis in human endothelial cells. J. Clin. Endocrinol. Metab. 89 (2004) 4594-4600
35. Kennedy A.M., Shogren K.L., Zhang M., Turner R.T., Spelsberg T.C., and Maran A. 17beta-estradiol-dependent activation of signal transducer and activator of transcription-1 in human fetal osteoblasts is dependent on Src kinase activity. Endocrinology 146 (2005) 201-207
36. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han L., et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104 (2001) 719-730